Log in
NASDAQ:OBSV

Obseva Stock Forecast, Price & News

$2.48
+0.02 (+0.81 %)
(As of 09/29/2020 12:00 AM ET)
Add
Compare
Today's Range
$2.43
Now: $2.48
$2.54
50-Day Range
$2.46
MA: $2.75
$2.98
52-Week Range
$1.63
Now: $2.48
$8.90
Volume344,756 shs
Average Volume762,607 shs
Market Capitalization$119.04 million
P/E RatioN/A
Dividend YieldN/A
Beta0.84
ObsEva SA, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for women suffering from reproductive health and pregnancy. It is developing Linzagolix, an oral gonadotropin-releasing hormone receptor antagonist for the treatment of pain associated with endometriosis and heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women; Nolasiban, an oral oxytocin receptor antagonist to enhance clinical pregnancy and live birth rates in women undergoing in vitro fertilization; and OBE022, an oral and selective prostaglandin F2a, or PGF2a receptor antagonist, as a once daily treatment for preterm labor in weeks 24 to 34 of gestational age. The company was founded in 2012 and is headquartered in Plan-les-Ouates, Switzerland.
Read More
Obseva logo

Beat the Market (BTM) Rank

Analyst Opinion: 4.3Community Rank: 2.3Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.64 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:OBSV
CUSIPN/A
Phone41-22-552-3840

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$1.01 per share

Profitability

Net Income$-108,790,000.00

Miscellaneous

Employees43
Market Cap$119.04 million
Next Earnings Date9/30/2020 (Estimated)
OptionableNot Optionable
$2.48
+0.02 (+0.81 %)
(As of 09/29/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive OBSV News and Ratings via Email

Sign-up to receive the latest news and ratings for OBSV and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Obseva (NASDAQ:OBSV) Frequently Asked Questions

How has Obseva's stock price been impacted by Coronavirus?

Obseva's stock was trading at $2.57 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, OBSV stock has decreased by 3.5% and is now trading at $2.48.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Obseva?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Obseva in the last year. There are currently 3 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Obseva
.

When is Obseva's next earnings date?

Obseva is scheduled to release its next quarterly earnings announcement on Wednesday, September 30th 2020.
View our earnings forecast for Obseva
.

How were Obseva's earnings last quarter?

Obseva SA (NASDAQ:OBSV) released its quarterly earnings results on Thursday, August, 6th. The company reported ($0.38) EPS for the quarter, topping the consensus estimate of ($0.42) by $0.04.
View Obseva's earnings history
.

What price target have analysts set for OBSV?

7 brokerages have issued 1 year price objectives for Obseva's stock. Their forecasts range from $4.00 to $36.00. On average, they anticipate Obseva's share price to reach $14.71 in the next year. This suggests a possible upside of 493.3% from the stock's current price.
View analysts' price targets for Obseva
.

Are investors shorting Obseva?

Obseva saw a decrease in short interest during the month of September. As of September 15th, there was short interest totaling 1,230,000 shares, a decrease of 29.7% from the August 31st total of 1,750,000 shares. Based on an average daily trading volume, of 883,800 shares, the short-interest ratio is presently 1.4 days. Approximately 3.7% of the company's shares are sold short.
View Obseva's Short Interest
.

Who are some of Obseva's key competitors?

What other stocks do shareholders of Obseva own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Obseva investors own include Sorrento Therapeutics (SRNE), SCYNEXIS (SCYX), Dynavax Technologies (DVAX), Matinas BioPharma (MTNB), Zosano Pharma (ZSAN), Trevena (TRVN), VBI Vaccines (VBIV), Vaxart (VXRT), BioNano Genomics (BNGO) and ADMA Biologics (ADMA).

Who are Obseva's key executives?

Obseva's management team includes the following people:
  • Dr. Ernest Loumaye, Co-Founder, CEO & Director (Age 67)
  • Mr. Timothy M. Adams, Chief Financial Officer (Age 59)
  • Dr. Jean-Pierre Gotteland Ph.D., Chief Scientific Officer and Head of R&D (Age 54)
  • Mr. Mario Vincent Corso, Sr. Director of Investor Relations
  • Dr. Elke Bestel M.D., Chief Medical Officer & Head of Pharmacovigilance (Age 53)

When did Obseva IPO?

(OBSV) raised $98 million in an IPO on Thursday, January 26th 2017. The company issued 6,500,000 shares at $14.00-$16.00 per share. Credit Suisse, Jefferies and Leerink Partners served as the underwriters for the IPO.

What is Obseva's stock symbol?

Obseva trades on the NASDAQ under the ticker symbol "OBSV."

How do I buy shares of Obseva?

Shares of OBSV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Obseva's stock price today?

One share of OBSV stock can currently be purchased for approximately $2.48.

How big of a company is Obseva?

Obseva has a market capitalization of $119.04 million. The company earns $-108,790,000.00 in net income (profit) each year or ($2.49) on an earnings per share basis. Obseva employs 43 workers across the globe.

What is Obseva's official website?

The official website for Obseva is www.obseva.com.

How can I contact Obseva?

Obseva's mailing address is Chemin des Aulx 12 Plan-les-Ouates, Geneva V8, 1228. The company can be reached via phone at 41-22-552-3840 or via email at [email protected].

This page was last updated on 9/30/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.